{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T16:03:12Z","timestamp":1784822592686,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s40120-026-00945-9","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:55:26Z","timestamp":1778079326000},"page":"1703-1719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Effectiveness and Safety of Ofatumumab: Analysis of B\u00a0Cell Depletion, Comorbidities and Ethnicity in a Spanish Cohort"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-6239","authenticated-orcid":false,"given":"Luis","family":"Moreno-Navarro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0746-1005","authenticated-orcid":false,"given":"Lourdes","family":"Ruiz-Escribano-Menchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8583-035X","authenticated-orcid":false,"given":"Josefa","family":"Polache-Vengud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1138-2388","authenticated-orcid":false,"given":"Ester","family":"Lobato-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0195-2834","authenticated-orcid":false,"given":"Angel P.","family":"Sempere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"issue":"6","key":"945_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1917246.","journal-title":"N Engl J Med"},{"key":"945_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2026.106994","volume":"107","author":"K Te\u0161ija","year":"2026","unstructured":"Te\u0161ija K, Krbot Skori\u0107 M, Ba\u0161i\u0107 Kes V, et al. Real-world effectiveness and safety of ofatumumab in relapsing multiple sclerosis: a multicenter cohort study. Mult Scler Relat Disord. 2026;107:106994. https:\/\/doi.org\/10.1016\/j.msard.2026.106994.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"945_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091568","volume":"61","author":"W Galus","year":"2025","unstructured":"Galus W, Kaczmarczyk A, Walawska-Hrycek A, et al. Real-world data of first 12-months of ofatumumab treatment in multiple sclerosis patients-a multicenter experience from tertiary referral centers. Medicina (Kaunas). 2025;61(9):1568. https:\/\/doi.org\/10.3390\/medicina61091568.","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"945_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00724","volume":"22","author":"CG Chisari","year":"2025","unstructured":"Chisari CG, Lo Fermo S, Iacono S, et al. Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: insights from na\u00efve and switch patients. Neurotherapeutics. 2025;22(6):e00724. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00724.","journal-title":"Neurotherapeutics"},{"issue":"6","key":"945_CR5","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s40120-025-00818-7","volume":"14","author":"G Ferrazzano","year":"2025","unstructured":"Ferrazzano G, Fantozzi R, Haggiag S, et al. Real-world 24-month outcomes of ofatumumab in relapsing multiple sclerosis: efficacy, safety, and the impact of frailty. Neurol Ther. 2025;14(6):2313\u201325. https:\/\/doi.org\/10.1007\/s40120-025-00818-7.","journal-title":"Neurol Ther"},{"key":"945_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105888","volume":"91","author":"CM Hersh","year":"2024","unstructured":"Hersh CM, Gorritz M, Chen CC, et al. Real-world persistence and adherence of ofatumumab versus oral and injectable disease-modifying therapies in patients with multiple sclerosis. Mult Scler Relat Disord. 2024;91:105888. https:\/\/doi.org\/10.1016\/j.msard.2024.105888.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"945_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1080\/17582024.2025.2452150","volume":"15","author":"M Amin","year":"2025","unstructured":"Amin M, Harvey T, Pineda DM, et al. Real world effectiveness, persistence, tolerability, and safety of ofatumumab in clinical practice. Neurodegener Dis Manag. 2025;15(1):27\u201336. https:\/\/doi.org\/10.1080\/17582024.2025.2452150.","journal-title":"Neurodegener Dis Manag"},{"issue":"10","key":"945_CR8","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","volume":"24","author":"X Montalban","year":"2025","unstructured":"Montalban X, Lebrun-Fr\u00e9nay C, Oh J, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025;24(10):850\u201365. https:\/\/doi.org\/10.1016\/S1474-4422(25)00270-4.","journal-title":"Lancet Neurol"},{"key":"945_CR9","unstructured":"European Medicines Agency (EMA). Kesimpta: Product Information. Amsterdam (Netherlands): EMA; 2021. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kesimpta-epar-product-information_en.pdf. Accessed Jan 2026."},{"key":"945_CR10","unstructured":"Neurostatus-UHB Ltd. Neurostatus-EDSS: Training and certification. Basel (Switzerland): Neurostatus-UHB Ltd; 2016. www.neurostatus.net. Accessed Jan 2026."},{"issue":"6","key":"945_CR11","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J, Sharmin S, Lorscheider J, et al. Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis. JAMA Neurol. 2025;82(6):614\u201325. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0495.","journal-title":"JAMA Neurol"},{"issue":"Pt 11","key":"945_CR12","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1093\/brain\/awv258","volume":"138","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Cutter G, Spelman T, et al. Defining reliable disability outcomes in multiple sclerosis. Brain. 2015;138(Pt 11):3287\u201398. https:\/\/doi.org\/10.1093\/brain\/awv258.","journal-title":"Brain"},{"issue":"9","key":"945_CR13","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/1352458517703193","volume":"23","author":"G Giovannoni","year":"2017","unstructured":"Giovannoni G, Tomic D, Bright JR, Havrdov\u00e1 E. \u201cNo evident disease activity\u201d: the use of combined assessments in the management of patients with multiple sclerosis. Mult Scler. 2017;23(9):1179\u201387. https:\/\/doi.org\/10.1177\/1352458517703193.","journal-title":"Mult Scler"},{"issue":"5","key":"945_CR14","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u201383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8.","journal-title":"J Chronic Dis"},{"issue":"7","key":"945_CR15","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1177\/13524585211028833","volume":"28","author":"ZY van Lierop","year":"2022","unstructured":"van Lierop ZY, Toorop AA, van Ballegoij WJ, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. 2022;28(7):1121\u20135. https:\/\/doi.org\/10.1177\/13524585211028833.","journal-title":"Mult Scler"},{"key":"945_CR16","unstructured":"Dati F, Schumann G, Thomas L, et al. Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC\/BCR\/CAP Reference Material (CRM 470). International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem. 1996;34(6):517\u201320."},{"key":"945_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.106191","volume":"93","author":"K Smolik","year":"2025","unstructured":"Smolik K, Camilli F, Panzera I, et al. Hypogammaglobulinemia and severe infections in multiple sclerosis patients on anti-CD20 agents: a multicentre study. Mult Scler Relat Disord. 2025;93:106191. https:\/\/doi.org\/10.1016\/j.msard.2024.106191.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"945_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1002\/ana.27143","volume":"97","author":"SG Meuth","year":"2025","unstructured":"Meuth SG, Wolff S, M\u00fcck A, et al. Different treatment outcomes of multiple sclerosis patients receiving ocrelizumab or ofatumumab. Ann Neurol. 2025;97(3):583\u201395. https:\/\/doi.org\/10.1002\/ana.27143.","journal-title":"Ann Neurol"},{"issue":"20","key":"945_CR19","doi-asserted-by":"publisher","first-page":"e1805","DOI":"10.1212\/WNL.0000000000005516","volume":"90","author":"A Bar-Or","year":"2018","unstructured":"Bar-Or A, Grove RA, Austin DJ, et al. Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study. Neurology. 2018;90(20):e1805\u201314. https:\/\/doi.org\/10.1212\/WNL.0000000000005516.","journal-title":"Neurology"},{"issue":"3","key":"945_CR20","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40263-020-00704-w","volume":"34","author":"F Sellebjerg","year":"2020","unstructured":"Sellebjerg F, Blinkenberg M, Sorensen PS. Anti-CD20 monoclonal antibodies for relapsing and progressive multiple sclerosis. CNS Drugs. 2020;34(3):269\u201380. https:\/\/doi.org\/10.1007\/s40263-020-00704-w.","journal-title":"CNS Drugs"},{"key":"945_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1004795","volume":"14","author":"J de S\u00e8ze","year":"2023","unstructured":"de S\u00e8ze J, Maillart E, Gueguen A, et al. Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic. Front Immunol. 2023;14:1004795. https:\/\/doi.org\/10.3389\/fimmu.2023.1004795.","journal-title":"Front Immunol"},{"issue":"1","key":"945_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-025-03668-0","volume":"23","author":"S Samadzadeh","year":"2025","unstructured":"Samadzadeh S, Szejko N, Hamadah Y, et al. CAR T\u00a0cells as novel therapeutic strategy for multiple sclerosis and other neuroimmune disorders. J Neuroinflammation. 2025;23(1):35. https:\/\/doi.org\/10.1186\/s12974-025-03668-0.","journal-title":"J Neuroinflammation"},{"issue":"4","key":"945_CR23","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200004","volume":"9","author":"MR von Essen","year":"2022","unstructured":"von Essen MR, Hansen RH, H\u00f8jgaard C, et al. Ofatumumab modulates inflammatory T\u00a0cell responses and migratory potential in patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9(4):e200004. https:\/\/doi.org\/10.1212\/NXI.0000000000200004.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"945_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/20552173251409954","volume":"12","author":"M Tanaka","year":"2026","unstructured":"Tanaka M, Kinoshita M, Tanaka K. T lymphopenia in multiple sclerosis patients treated with ofatumumab: even with consideration for CD3+ CD20+ cells. Mult Scler J Exp Transl Clin. 2026;12(1):20552173251409954. https:\/\/doi.org\/10.1177\/20552173251409954.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"11-12","key":"945_CR25","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1177\/13524585231195346","volume":"29","author":"SL Hauser","year":"2023","unstructured":"Hauser SL, Zielman R, Das Gupta A, et al. Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension. Mult Scler. 2023;29(11\u201312):1452\u201364. https:\/\/doi.org\/10.1177\/13524585231195346.","journal-title":"Mult Scler"},{"key":"945_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2025.106617","volume":"102","author":"MH Tai","year":"2025","unstructured":"Tai MH, Brown B, Taiji R, et al. Real-world change in annualized relapse rate and healthcare resource utilization following initiation of ofatumumab in people with multiple sclerosis. Mult Scler Relat Disord. 2025;102:106617. https:\/\/doi.org\/10.1016\/j.msard.2025.106617.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"945_CR27","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1212\/WNL.0000000000004885","volume":"90","author":"T Zhang","year":"2018","unstructured":"Zhang T, Tremlett H, Zhu F, et al. Effects of physical comorbidities on disability progression in multiple sclerosis. Neurology. 2018;90(5):e419\u201327. https:\/\/doi.org\/10.1212\/WNL.0000000000004885.","journal-title":"Neurology"},{"issue":"2","key":"945_CR28","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1159\/000539829","volume":"60","author":"S Iacono","year":"2026","unstructured":"Iacono S, Schir\u00f2 G, Aridon P, et al. Performance of a modified version of the Charlson Comorbidity Index in predicting multiple sclerosis disability accrual. Neuroepidemiology. 2026;60(2):203\u201313. https:\/\/doi.org\/10.1159\/000539829.","journal-title":"Neuroepidemiology"},{"key":"945_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00168-025-01370-w","volume":"74","author":"AG Sanchis","year":"2025","unstructured":"Sanchis AG, Remoaldo P, Martinez-de-Ibarreta C. Migrations in Spain: econometric models with demographic and economic variables (1950\u20132021). Ann Reg Sci. 2025;74:41. https:\/\/doi.org\/10.1007\/s00168-025-01370-w.","journal-title":"Ann Reg Sci"},{"key":"945_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105153","volume":"81","author":"G Mallawaarachchi","year":"2024","unstructured":"Mallawaarachchi G, Rog DJ, Das J. Ethnic disparities in the epidemiological and clinical characteristics of multiple sclerosis. Mult Scler Relat Disord. 2024;81:105153. https:\/\/doi.org\/10.1016\/j.msard.2023.105153.","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"945_CR31","doi-asserted-by":"publisher","first-page":"e880","DOI":"10.1212\/WNL.0000000000013230","volume":"98","author":"HM Onuorah","year":"2022","unstructured":"Onuorah HM, Charron O, Meltzer E, et al. Enrollment of non-White participants and reporting of race and ethnicity in phase\u00a0III trials of multiple sclerosis DMTs: a systematic review. Neurology. 2022;98(9):e880\u201392. https:\/\/doi.org\/10.1212\/WNL.0000000000013230.","journal-title":"Neurology"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00945-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00945-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T15:11:31Z","timestamp":1784819491000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00945-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00945-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship, and\/or publication of this article: Luis Moreno-Navarro has received speaking honoraria or travel expenses for participation in scientific meetings from AbbVie, Bristol Myers Squibb, Esteve, Juvis\u00e9 Pharmaceuticals, Kern Pharma, Merck, Neuraxpharm, Novartis, Roche, Sandoz, and Sanofi. Lourdes Ruiz-Escribano-Menchen declares fees for lectures or assistance to congresses from Alter, Bristol Myers Squibb, Daiichi Sankyo, Merck, Novartis, and Roche. Angel P. Sempere has received personal compensation from Merck Serono, Novartis, Roche, and Sandoz for serving on a scientific advisory board or speaking. Josefa Polache-Vengud and Ester Lobato-Martinez have nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Helsinki Declaration of 1964, and its later amendments, and approved by the Ethics Committee for Medical Research of the Health Department of Alicante General Hospital, Spain (Reference 2025-0199). All participants provided written informed consent to participate in the study.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}